Rhumbline Advisers Dexcom Inc Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Dexcom Inc stock. As of the latest transaction made, Rhumbline Advisers holds 776,229 shares of DXCM stock, worth $67.4 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

776,229

Previous 805,663 3.65%

Holding current value

$67.4 Million

Previous $54 Million 11.8%

% of portfolio

0.06%

Previous 0.05%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	SELL	$65.68 - $81.01 $1.93 Million - $2.38 Million	-29,434 Reduced 3.65%	776,229 $60.4 Million
Q3 2024 Nov 12, 2024	BUY	$64.0 - $116.06 $19,584 - $35,514	306 Added 0.04%	805,663 $54 Million
Q2 2024 Aug 01, 2024	BUY	$110.31 - $140.45 $1.97 Million - $2.5 Million	17,817 Added 2.26%	805,357 $91.3 Million
Q1 2024 May 09, 2024	BUY	$114.22 - $140.1 $1.1 Million - $1.35 Million	9,661 Added 1.24%	787,540 $109 Million
Q4 2023 Feb 08, 2024	SELL	$75.49 - $124.16 $858,774 - $1.41 Million	-11,376 Reduced 1.44%	777,879 $96.5 Million
Q3 2023 Nov 09, 2023	BUY	$86.06 - $137.93 $11,445 - $18,344	133 Added 0.02%	789,255 $73.6 Million
Q2 2023 Aug 08, 2023	BUY	$112.47 - $130.98 $592,379 - $689,871	5,267 Added 0.67%	789,122 $101 Million
Q1 2023 May 11, 2023	BUY	$104.0 - $122.92 $4.94 Million - $5.83 Million	47,461 Added 6.45%	783,855 $91.1 Million
Q4 2022 Feb 14, 2023	BUY	$84.98 - $122.67 $1.34 Million - $1.94 Million	15,818 Added 2.2%	736,394 $83.4 Million
Q3 2022 Nov 10, 2022	BUY	$76.35 - $94.18 $920,933 - $1.14 Million	12,062 Added 1.7%	720,576 $58 Million
Q2 2022 Aug 11, 2022	BUY	$67.99 - $132.89 $36.8 Million - $72 Million	541,883 Added 325.2%	708,514 $52.8 Million
Q1 2022 May 12, 2022	SELL	$94.08 - $130.2 $22,767 - $31,508	-242 Reduced 0.15%	166,631 $85.2 Million
Q4 2021 Feb 10, 2022	BUY	$129.87 - $162.82 $107,142 - $134,326	825 Added 0.5%	166,873 $89.6 Million
Q3 2021 Nov 12, 2021	SELL	$106.71 - $143.18 $66,480 - $89,201	-623 Reduced 0.37%	166,048 $90.8 Million
Q2 2021 Aug 05, 2021	SELL	$80.99 - $107.93 $103,262 - $137,610	-1,275 Reduced 0.76%	166,671 $71.2 Million
Q1 2021 May 06, 2021	SELL	$84.79 - $104.74 $562,666 - $695,054	-6,636 Reduced 3.8%	167,946 $60.4 Million
Q4 2020 Feb 10, 2021	BUY	$78.0 - $104.5 $86,814 - $116,308	1,113 Added 0.64%	174,582 $64.5 Million
Q3 2020 Nov 12, 2020	BUY	$95.51 - $112.95 $240,398 - $284,295	2,517 Added 1.47%	173,469 $71.5 Million
Q2 2020 Aug 13, 2020	BUY	$62.68 - $105.34 $4.73 Million - $7.95 Million	75,433 Added 78.97%	170,952 $69.3 Million
Q1 2020 May 06, 2020	SELL	$47.79 - $75.63 $81,099 - $128,344	-1,697 Reduced 1.75%	95,519 $25.7 Million
Q4 2019 Feb 05, 2020	BUY	$36.62 - $57.29 $75,144 - $117,559	2,052 Added 2.16%	97,216 $21.3 Million
Q3 2019 Oct 23, 2019	SELL	$35.53 - $43.8 $29,312 - $36,135	-825 Reduced 0.86%	95,164 $14.2 Million
Q2 2019 Aug 14, 2019	SELL	$27.84 - $38.92 $100,418 - $140,384	-3,607 Reduced 3.62%	95,989 $14.4 Million
Q1 2019 May 01, 2019	SELL	$28.07 - $38.18 $44,238 - $60,171	-1,576 Reduced 1.56%	99,596 $11.9 Million
Q4 2018 Jan 31, 2019	SELL	$26.99 - $37.37 $5,074 - $7,025	-188 Reduced 0.19%	101,172 $12.1 Million
Q3 2018 Nov 07, 2018	BUY	$23.35 - $36.72 $4,436 - $6,976	190 Added 0.19%	101,360 $14.5 Million
Q2 2018 Aug 06, 2018	BUY	$17.54 - $25.22 $40,640 - $58,434	2,317 Added 2.34%	101,170 $9.61 Million
Q1 2018 May 02, 2018	SELL	$13.06 - $18.54 $37,978 - $53,914	-2,908 Reduced 2.86%	98,853 $7.33 Million
Q4 2017 Feb 09, 2018	SELL	$11.12 - $15.38 $20,772 - $28,729	-1,868 Reduced 1.8%	101,761 $5.84 Million
Q3 2017 Nov 06, 2017	BUY	$11.36 - $18.98 $1.18 Million - $1.97 Million	103,629	103,629 $5.07 Million

Others Institutions Holding DXCM

# of Institutions

1,023

Shares Held

353M

Call Options Held

5.51M

Put Options Held

5.61M

View Full List

About DEXCOM INC

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $33.5B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

More about DXCM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Dexcom Inc Transaction History